查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1891240

抗体药物偶联物 (ADC) 合约生产市场（第七版）：依研发阶段、製程组件、有效载荷、抗体同型、标靶适应症、抗体来源、连接子和主要地区划分——产业趋势及全球预测至 2035 年

ADC Contract Manufacturing Market (7th Edition): Distribution by Stage of Development, Process Component, Payload, Antibody Isotype, Target Indication, Antibody Origin, Linker, and Key Geographical Regions - Industry Trends and Forecast 2025-2035
出版日期: | 出版商: Roots Analysis | 英文 451 Pages | 商品交期: 最快1-2个工作天内

价格

ADC 合约生产市场：概述

预计 ADC 合约生产市场将从 2025 年的 17.2 亿美元成长到 2035 年的 32.12 亿美元，2025 年至 2035 年的复合年增长率 (CAGR) 为 6.4%。

业务规模

  • 临床规模
  • 商业规模

製程组件

  • 微管蛋白抑制剂
  • 拓朴异构酶抑制剂
  • DNA 损伤剂
  • 其他

有效载荷类型

  • 微管蛋白抑制剂
  • 拓朴异构酶抑制剂
  • DNA损伤剂
  • 其他

抗体同工型

  • IgG1
  • IgG4
  • 其他

标靶适应症

  • 实体瘤
  • 血液系统恶性肿瘤

连接子类型

  • 缬氨酸-瓜氨酸连接子
  • SMCC连接子
  • 腙连接子
  • 马来酰亚胺连接子
  • 马来酰亚胺己酰连接子
  • 四肽连接子
  • 胜肽连接子
  • 其他

抗体起始点

  • 人形化
  • 嵌合体
  • 人类
  • 其他

主要地区

  • 北美洲
  • 美国
  • 加拿大
  • 其他北美洲国家
  • 欧洲
  • 英国
  • 西班牙
  • 义大利
  • 德国
  • 法国
  • 其他欧洲国家
  • 亚太及其他地区
  • 中国
  • 日本
  • 印度
  • 韩国
  • 澳大利亚
  • 阿根廷
  • 巴西
  • 智利
  • 哥伦比亚
  • 以色列
  • 肯亚
  • 秘鲁
  • 南非
  • 土耳其
  • 沙乌地阿拉伯
  • 其他地区全球

ADC 合约生产市场：成长与趋势

近年来，抗体药物偶联物 (ADC) 在治疗包括实体肿瘤和血液系统恶性肿瘤在内的多种癌症方面展现出巨大的潜力。这些复杂的分子由抗体透过化学偶联物与具有生物活性的细胞毒性药物连接而成，已证实具有更高的稳定性、靶向特异性、肿瘤选择性和药物动力学特性。

目前，ADC 研发管线包含超过 614 种正在进行临床试验的候选药物，以及 28 个已获得监管机构批准的 ADC 治疗计画。 ADC 的生产流程需要专业知识和先进技术的应用，这两者都成本高昂。因此，ADC 开发商更倾向于将生产业务外包给 ADC 合约生产商 (CMO)。利用这些 CMO 的专业知识、资源和生产设施，开发商可以降低成本并缩短研发週期。受抗体偶联药物 (ADC) 需求不断增长以及药物研发外包趋势日益盛行的推动，ADC 合约生产市场预计将在预测期内显着增长。

ADC 合约生产市场：关键洞察

本报告深入分析了 ADC 合约生产市场的现状，并指出了该行业潜在的成长机会。主要发现包括：

  • 在当前市场格局中，全球约有 35 家公司声称具备提供抗体药物偶联物 (ADC) 合约生产和偶联服务的必要能力。
  • 大多数製造商（约占 65%）提供各种规模的业务服务，提供一站式服务，帮助客户解决技术难题，例如技术转移和规模化生产。
ADC 合约製造市场-IMG1
  • 各利害关係人正积极提升现有能力，以增强自身产品组合，并在 ADC 合约製造领域获得相对于其他公司的竞争优势。
  • 产业参与者已投入大量精力加强基础设施建设并拓展服务范围，其中大部分措施是在过去 12 个月内实施的。
  • 近年来，各利益相关者签署的合作协议数量不断增加，也反映出市场对该领域的日益增长的兴趣。事实上，约 60% 的交易是在过去三年内签署的。
ADC 合约生产市场-IMG2
  • 迄今为止，已有超过 780 项评估各种抗体药物偶联物 (ADC) 安全性和有效性的临床试验入组，其中大部分研究在美国各地的医疗机构进行。
  • 预计 ADC 疗法开发商将与合约生产服务提供者建立策略联盟，以外包复杂的生产流程。
  • ADC 的开发需要选择抗体、连接子和细胞毒性有效载荷，以靶向细胞内化的高表达肿瘤抗原。
  • 值得注意的是，超过 30% 的产能扩张计画由北美公司实施，这反映了该地区在先进 ADC 生产基础设施方面的领先地位。
  • 全球抗体药物偶联物 (ADC) 的生产能力分布广泛，遍布各地区。值得注意的是，约 90% 的总产能集中在大型公司拥有的工厂。
  • 随着多个临床候选药物预计将在各个地区商业化，对 ADC 疗法的需求可能会显着增长。
  • 在不断扩大的 ADC 治疗产品线和合约服务提供者的生产技术驱动下，ADC 合约生产市场预计未来将显着成长。
ADC 合约生产市场-IMG3
  • 目前，欧洲占市场主导地位（45%），是 ADC 合约生产市场中占有率最大的地区，其次是北美。
  • 由于其高安全性和低免疫原性，预计人源化抗体药物偶联物（ADC）细分市场今年将占大部分市场占有率。
  • 预计到2035年，北美ADC合约生产市场将占最大占有率。此外，该领域约85%的公司提供抗体生产服务。

ADC合约生产市场：主要细分市场

商业规模生产占ADC合约生产市场最大占有率

就营运规模而言，ADC合约生产市场可细分为临床和商业等不同规模。目前，由于市场对ADC作为强效标靶癌症疗法的需求不断增长，商业规模细分市场占了更大的市场占有率（约90%）。预计在预测期内，临床阶段细分市场将以较高的复合年增长率（7.6%）成长。这是由于2021年后监管机构批准了大量ADC候选药物。 ADC疗法的进展正促使越来越多的ADC进入临床开发阶段。

预计实体肿瘤领域将占ADC合约生产市场最大的收入占有率。

今年，实体瘤领域预计将占ADC合约生产市场的大部分占有率（80%），而这一趋势预计将持续。这种主导地位源自于大多数市售ADC疗法和目前正在进行临床试验的疗法都专注于实体肿瘤。预计血液肿瘤市场在预测期内将以8.7%的复合年增长率成长。

预计未来抗体将占ADC合约生产市场最大的占有率。

今年，抗体领域占了整个市场最大的占有率，而这一趋势预计将在整个预测期内持续。抗体的高占比源自于复杂的细胞或蛋白质工程要求，这使得抗体生产成为一个耗时且成本高昂的过程。因此，需要更专业的抗体生产技术。

亚太地区预计将引领抗体药物偶联物（ADC）合约生产市场。

预计亚太地区及世界其他地区的市场在预测期内将以相对较高的复合年增长率（8.5%）增长。这主要得益于该地区，尤其是中国和印度等国家所具有的显着成本优势。与北美和欧洲的传统生产地相比，这些国家拥有更低的劳动力成本和营运成本，从而提供了更有利的生产环境。总部位于亚太地区的ADC合约生产公司包括Shilpa Biologics、药明生物、台塑製药、Syngene和三星生物。

ADC 合约生产市场代表性公司

  • 艾伯维合约生产
  • Abzena
  • CARBOGEN AMCIS
  • Catalent Pharma Solutions
  • Cerbios-Pharma
  • MabPlex
  • Millipore Sigma
  • Lonza
  • 药明生物

ADC 合约生产市场：研究范围

  • 市场规模和机会分析：本报告对 ADC 合约生产市场进行了详细分析，重点关注以下关键市场细分：[A] 研发阶段，[B] 製程组成，[C] 有效载荷类型，[D] 抗体亚型，[E] 靶向适应症，[F] 抗体来源，[G] 连接子类型，以及 [H] 主要地区。
  • 市场概况：基于以下相关参数，对参与ADC合约製造的关键公司进行全面评估：[A] 成立年份，[B] 公司规模，[C] 总部所在地，[D] 提供的ADC製造服务类型，[E] 提供的附加服务类型，[F] 製造工厂规模，[G] 製造工厂所在地。
  • 公司简介：详细介绍总部位于北美、欧洲和亚太地区的ADC製造公司。主要内容包括：[A] 公司概况，[B] ADC合约製造产品组合，[C] 近期发展，以及[D] 未来展望。
  • 公司竞争力分析：对ADC合约製造公司进行全面的竞争分析。检视以下因素：[A] 供应商实力，[B] 服务实力，以及[C] 製造工厂数量。
  • 合作伙伴关係与合作：ADC 合约製造市场利害关係人的合作伙伴关係状况分析，分析维度包括：[A] 合作伙伴关係成立年份，[B] 合作伙伴关係形式，[C] 合作伙伴关係年份和形式，[D] 合作活动等的地理分布
  • 近期扩张趋势：基于以下相关参数，详细分析各抗体药物偶联物 (ADC) 合约生产商的近期扩张趋势：基于以下相关参数，详细分析各抗体药物偶联物 (ADC) 合约生产商的近期扩张活动：[A] 扩张年份，[B] 扩张类型，[C] 辅料类型，[D] 扩张活动：[A] 扩张年份，[B] 扩张类型，[C] 辅料类型，[D] 扩张活动（依地区/国家），[E] 扩张年，[B] 辅料类型，[D] 扩张类型（依地区/国家），[E] 扩张设施位置（依地区），[F] 设施位置（依地区/国家/国家/地区），扩展
  • 产能分析：估算全球抗体合约生产的已安装产能。这考虑了各 ADC 合约生产商基于多个相关参数的生产能力，例如 [A] 公司规模，[B] 营运规模，以及 [C] 主要地理区域。
  • 内部生产与外包决策：对ADC合约生产市场目前及未来机会进行详细评估，评估内容涵盖不同的製程环节，例如[A]抗体、[B]高活性药物成分/细胞毒性有效载荷、[C]偶联/连接子以及[D]填充/包装。
  • 价值链分析：详细检视ADC生产的每个步骤（抗体生产、有效载荷生产、连接子生产、偶联、填充和包装），并提供各阶段的成本资讯。
  • 案例研究：概述目前ADC市场格局，并基于以下相关参数对ADC产品线进行详细分析：[A]研发频率、[B]标靶疾病领域、[C]治疗领域、[D]治疗线、[E]给药频率、[F]治疗类型、[G]标靶抗原、[H]抗体同型、[I]活性成分/细胞毒性药物。 [C] 治疗领域，[D] 治疗线，[E] 给药频率，[F] 治疗类型，[G] 标靶抗原，[H] 抗体亚型，[I] 有效载荷/细胞毒性药物/弹头，[J] 有效载荷类型，[K] 连接子类型。
  • 临床试验分析：基于以下相关参数，对已完成、正在进行和计划中的各种抗体药物偶联物 (ADC) 临床试验进行详细分析：[A] 研究註册年份，[B] 入组患者人数，[C] 研究阶段，[D] 研究状态，[E] 目标患者人群，[F] 患者性别，[G] 申办人最活跃的参与者（基于註册研究数量），[J] 地理位置。 [G] 申办者/合作方类型，[H] 研究设计，[I] 最活跃的参与者（基于註册研究数量），[J] 地区。
  • 潜在合作分析：基于相关参数（例如[A] 开发商实力、[B] 产品线实力、[C] 成熟度以及[D] 生产能力），对具有与ADC合约生产商建立高合作潜力的ADC疗法开发商进行详细分析。
  • 需求分析：基于相关参数（例如[A] 目标患者群体、[B] 给药频率、[C] 剂量强度以及[D] 已获批产品和临床阶段候选药物的临床阶段候选药物），对ADC疗法的年度商业和临床需求（以公斤为单位）进行合理估算。
  • 区域产能分析：提供详细的区域产能评估框架，比较关键区域。比较参数包括[A] ADC合约生产商数量、[B] ADC生产设施数量、[C] 设施扩建数量、[D] 已安装的ADC生物偶联产能、[E] 已註册的临床试验数量以及[F] 该地区的ADC需求。
  • 吸引力竞争矩阵：对当前市场状况进行详细评估，包括现有竞争格局以及新兴和成熟市场细分领域的成长机会。
  • 市场影响分析：对可能影响ADC合约製造市场成长的因素进行详细分析。这包括识别和市场分析以下方面：[A] 关键驱动因素，[B] 潜在限制因素，[C] 新兴机遇，以及 [D] 现有挑战。

目录

第一章：引言

第二章：研究方法

第三章：市场动态

  • 章节概述
  • 预测研究法
  • 市场估值框架
  • 预测工具与技术
  • 关键考虑因素
  • 局限性

第四章：宏观经济指标

  • 章节概述
  • 市场动态
  • 结论

第五章：摘要整理

第六章：引言

  • 章节概述
  • 关键组成部分ADC（抗体偶联药物）
  • ADC 製造
  • 供应链挑战与方法论转移
  • 选择 CMO 合作伙伴
  • 未来展望

第七章：市场概况

  • 章节概述
  • ADC 代工製造商：市场概况

第八章：竞争分析

  • 章节概述
  • 假设与关键参数
  • 研究方法
  • ADC 代工製造商：竞争分析
  • 顶级 ADC 代工製造商的能力标竿分析

第九章 ADC 代工製造商公司简介

  • 章节概述
  • MabPlex
  • Lonza
  • Abzena
  • GBI
  • CARBOGEN AMICS
  • Millipore Sigma
  • WuXi Biologics
  • Catalent Pharma Solutions
  • Cerbios-Pharma
  • Formosa Laboratories
  • Sterling Pharma Solutions
  • Piramal Pharma Solutions
  • AbbVie Contract Manufacturing

第十章 近期扩张

  • 章节概述
  • ADC 合约製造商：近期扩张

第十一章 合作关係

章节第 12 章：自製或外购决策

  • 章节概述
  • 假设和关键参数
  • 结论

第 13 章：价值链分析

  • 章节概述
  • ADC 开发价值链
  • 价值链成本分配

第 14 章：产能分析

  • 章节概述
  • 关键假设与研究方法
  • ADC 生产：全球已安装产能

第 15 章：个案研究：ADC 治疗市场概况

  • 章节概述
  • ADC 治疗：治疗管线
  • 抗体药物偶联物：值得关注的疗法
  • 结论

第16章 临床试验分析

  • 章节概述
  • 研究范围与方法
  • 抗体药物偶联物：临床试验分析

第17章：潜在合作伙伴分析

  • 章节概述
  • 评分标准与关键假设
  • 研究范围与方法
  • 北美潜在策略伙伴
  • 欧洲潜在战略伙伴
  • 亚太及其他地区潜在战略伙伴

第18章：ADC疗法：需求分析

第19章：区域能力分析

第20章：吸引力与竞争力矩阵

  • 章节概述
  • AC矩阵：概述
  • AC矩阵：分析研究方法
  • AC矩阵：ADC合约製造市场整体概况

第21章 市场影响分析

  • 章节概述
  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场挑战
  • 结论

第22章：全球ADC合约製造市场

第23章：ADC合约製造市场（依业务规模划分）

第24章：ADC合约製造市场（依製程组件划分）

第25章：ADC合约製造市场（依有效载荷类型划分））

第26章：ADC合约生产市场（依抗体来源划分）

第27章：ADC合约生产市场（以抗体同型划分）

第28章：ADC合约生产市场（以标靶适应症划分）

第29章：ADC合约生产市场（依连接子类型划分）

第30章：ADC合约生产市场（依主要地区划分）

第31章：商业化ADC合约生产市场

第32章：临床ADC合约生产市场

第33章：结论

第34章：高阶主管洞察

第35. 附录一：表格资料

第36章 附录二：公司与组织清单

Product Code: RA100365

ADC Contract Manufacturing Market: Overview

As per Roots Analysis, the ADC contract manufacturing market is estimated to grow from USD USD 1,720 million in 2025 in the current year to USD 3,212 million by 2035 at a CAGR of 6.4% during the forecast period, till 2035.

Scale of Operation

  • Clinical Scale
  • Commercial Scale

Process Component

  • Tubulin Inhibitors
  • Topoisomerase Inhibitors
  • DNA Damaging Agents
  • Others

Type of Payload

  • Tubulin Inhibitors
  • Topoisomerase Inhibitors
  • DNA Damaging Agents
  • Others

Antibody Isotype

  • IgG1
  • IgG4
  • Others

Target Indication

  • Solid Tumors
  • Hematological Malignancies

Type of Linker

  • Valine-citrulline
  • SMCC
  • Hydrazone
  • Maleimide
  • Maleimidocaproyl
  • Tetrapeptide-based linker
  • Peptide Linker
  • Others

Antibody Origin

  • Humanized
  • Chimeric
  • Human
  • Others

Key Geographical Regions

  • North America
  • US
  • Canada
  • Rest of North America
  • Europe
  • UK
  • Spain
  • Italy
  • Germany
  • France
  • Rest of Europe
  • Asia-Pacific and Rest of the World
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Argentina
  • Brazil
  • Chile
  • Columbia
  • Israel
  • Kenya
  • Peru
  • South Africa
  • Turkey
  • Saudi Arabia
  • Rest of Asia-Pacific and rest of the world

ADC Contract Manufacturing Market: Growth and Trends

Antibody drug conjugates (ADCs) have shown remarkable promise in recent years for the treatment of various cancers, encompassing both solid tumors and hematological malignancies. These intricate molecules, consisting of an antibody linked to biologically active, cytotoxic substances via chemical connectors, demonstrate improved stability, target specificity, tumor selectivity, and pharmacokinetic characteristics.

At present, the ADC pipeline comprises more than 614 drug candidates in clinical trial assessment, in addition to 28 ADC therapeutic programs that have received approval from different regulatory bodies. The production process for ADC necessitates specialized knowledge and the application of advanced technologies, both of which are cost intensive. Consequently, ADC developers favor delegating manufacturing tasks to ADC contract manufacturers. By utilizing the expertise, resources, and production facilities of these CMOs, developers can streamline costs and speed up schedules. Due to the rising demand for ADCs and the growing tendency for drug developers to outsource operations, the ADC contract manufacturing market is expected to experience significant growth throughout the forecast period.

ADC Contract Manufacturing Market: Key Insights

The report delves into the current state of the ADC contract manufacturing market and identifies potential growth opportunities within the industry. Some key findings from the report include:

  • The current market landscape features a presence of close to 35 companies that claim to have the required capabilities to offer contract manufacturing and conjugation services for antibody drug conjugates, worldwide.
  • Majority (~65%) of the manufacturers offer different types of services across all scales of operation, in order to become one-stop shops for mitigating technical challenges such as technology transfer and scale-up for clients.
ADC Contract Manufacturing Market - IMG1
  • Stakeholders are actively upgrading their existing capabilities in order to enhance their respective portfolios and gain a competitive edge over other players active in the ADC contract manufacturing domain.
  • Industry players are undertaking significant efforts to strengthen their infrastructure and enhance service offerings in this domain, with most of the initiatives undertaken in the last 12 months.
  • The rising interest in this market is reflected from the rising partnerships established among various stakeholders in the recent past; in fact, close to 60% of the deals were inked in the last three years.
ADC Contract Manufacturing Market - IMG2
  • More than 780 clinical trials have been registered till date to evaluate the safety and efficacy of various antibody drug conjugates; majority of these studies have been conducted across various sites in the US.
  • Various ADC therapeutic developers are anticipated to forge strategic alliances with contract manufacturing service providers in order to outsource complex manufacturing operations.
  • The deployment of ADCs requires the selection of antibody, linker, and cytotoxic payload, in order to target high-expression tumor antigens that are internalized by the cell.
  • Notably, over 30% of the total capacity expansion initiatives were carried out by the players located in North America, reflecting the region's dominance in advanced ADC manufacturing infrastructure.
  • The global installed antibody drug conjugates manufacturing capacity is well distributed across various geographies; interestingly, around 90% of total installed capacity is available in facilities owned by large players.
  • The demand for ADC therapeutics is likely to increase significantly as several clinical candidates are expected to be commercialized across various regions.
  • Driven by the expanding pipeline of ADC therapeutics and manufacturing expertise available with contract service providers, the ADC contract manufacturing market is poised to witness significant growth in the future.
ADC Contract Manufacturing Market - IMG3
  • Europe currently dominates the market (45%) and captures the largest share within the ADC contract manufacturing market; this is followed by North America.
  • The humanized sub-segment is estimated to capture majority of the overall market share in the current year, owing to its enhanced safety and reduced immunogenicity.
  • The ADC contract manufacturing market in North America is expected to capture maximum share by 2035; further, close to 85% of the companies in this domain offer services for antibody manufacturing.

ADC Contract Manufacturing Market: Key Segments

Commercial Scale of Operation Accounts for the Largest Share of ADC Contract Manufacturing Market

In terms of scale of operation, the ADC contract manufacturing market is segmented across various scales of operation such as clinical and commercial scale. Currently, the commercial scale segment occupies the higher market share (around 90%), owing to the surging demand for ADCs as potent targeted cancer therapies. The clinical segment is likely to grow at a higher CAGR (7.6%) during the forecast period. This stems from many ADC drug candidates authorized by regulatory agencies since 2021. Advancements in ADC therapies have led to a growing quantity of ADCs moving into the clinical development phase.

Solid Tumors Segment to Hold the Highest Revenue in the ADC Contract Manufacturing Market

In the current year, solid tumors segment is likely to capture majority of the ADC contract manufacturing market size (with a share of 80%), and this trend is unlikely to change in the future as well. This prevalence arises from the fact that the majority of commercialized ADC therapeutics and those in advanced clinical trials specifically for solid tumors. The market for hematologic cancers is expected to expand at a CAGR of 8.7% during the forecast period.

Antibodies are Likely to Hold the Highest ADC Contract Manufacturing Market Share in the Future

In the current year, the antibody segment occupies the highest share in the overall market and this trend is expected to remain same during the forecast period. The higher share of antibodies is due to the complex cellular or protein engineering requirements, making antibody manufacturing a time and cost-intensive process, thus prompting the need for more specialized antibody manufacturing expertise.

Asia-Pacific is Likely to Propel the ADC Contract Manufacturing Market

The market in Asia-Pacific and rest of the world is likely to grow at a relatively higher CAGR (8.5%), during the forecast period. This is a result of significant cost advantage offered by this region, particularly in countries such as China and India, where lower labor costs and operational expenses provide favorable manufacturing environment as compared to traditional hubs in North America and Europe. Examples of ADC contract manufacturing companies based in Asia-Pacific include Shilpa Biologics, WuXi Biologics, Formosa Laboratories, Syngene and Samsung Biologics.

Example Players in the ADC Contract Manufacturing Market

  • AbbVie Contract Manufacturing
  • Abzena
  • CARBOGEN AMCIS
  • Catalent Pharma Solutions
  • Cerbios-Pharma
  • MabPlex
  • Millipore Sigma
  • Lonza
  • WuXi Biologics

Primary Research Overview

Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The market report includes transcripts of the following discussions:

  • Senior Director, Commercial Development, Large company, Europe
  • Business Development Manager, Mid-sized company, Europe
  • Chief Executive Officer, Large company, Europe
  • Chief Executive Officer and Founder, Small Company, UK
  • Chief Executive Officer and Co-Founder, Small Company, France
  • Former Chief Executive Officer, Large Company, US
  • Chief Commercial Officer, Mid-sized Company, Switzerland
  • Chief Business Officer, Small Company, Switzerland
  • Executive Director, Large Company, Japan and Chief Innovation Officer, Large Company, Japan
  • Director, Business Development, Small Company, Netherlands
  • Director Corporate Development, Mid-sized Company, US
  • Director, Business Development, Large Company, US and Former Group Product Manager, Large Company, US
  • Former Director of CDMO, Large Organization, France
  • Business Development Manager, Mid-sized Company, Switzerland
  • Former Head of Bioconjugates Commercial Development, Large Company, Switzerland
  • Former Site Head, Large Company, US
  • Associate Scientist, Large Company, US

ADC Contract Manufacturing Market: Research Coverage

  • Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the ADC contract manufacturing market, focusing on key market segments, including [A] stage of development, [B] process component, [C] type of payload, [D] antibody isotype, [E] target indication, [F] antibody origin, [G] type of linker and [H] key geographical regions.
  • Market Landscape: A comprehensive evaluation of overall market landscape of players engaged in the contract manufacturing of ADCs, based on several relevant parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters, [D] type of ADC manufacturing service offered, [E] type of additional service offered, [F] scale of and [G] location of manufacturing facility.
  • Company Profiles: In-depth profiles of companies engaged in the manufacturing of ADCs headquartered in North America, Europe and Asia-Pacific focusing on [A] company overview, [B] ADC contract manufacturing portfolio, [C] recent developments and [D] an informed future outlook.
  • Company Competitiveness Analysis: A comprehensive competitive analysis of ADC contract manufacturers, examining factors, such as [A] supplier strength, [B] service strength and [C] number of manufacturing facilities.
  • Partnerships and Collaborations: A detailed analysis of the partnerships inked between stakeholders in the ADC contract manufacturing market based on several relevant parameters, such as [A] year of partnership, [B] type of partnership, [C], year and type of partnership and [D], geographical distribution of partnership activity.
  • Recent Expansions: A detailed analysis of the recent expansions undertaken by various ADC contract manufacturers, based on several relevant parameters, such as [A] year of expansion, [B] type of expansion, [C] type of excipient, [D] type of expansion (region and country), [E] location of expanded facility (region), [F] location of expanded facility (country), [G] most active players (in terms of number of recent expansions) and [H] geographical distribution (region and country).
  • Capacity Analysis: An estimate of the global installed capacity for antibody contract manufacturing taking into consideration the capacities of various ADC contract manufacturers, based on several relevant parameters, such as [A] company size, [B] scale of operation and [C] key geographical regions.
  • Make Versus Buy Decision Making: A detailed evaluation of current and future opportunity within the ADC contract manufacturing market across different process components, such as [A] antibody, [B] HPAPI / cytotoxic payload, [C] conjugation / linker and [D] fill / finish.
  • Value Chain Analysis: A detailed discussion on various steps (antibody manufacturing, payload manufacturing, linker manufacturing, conjugation and fill / finish) involved in the manufacturing of ADCs, along with information on the cost requirements across each stage.
  • Case Study: An overview of the current market landscape of ADCs, along with detailed analysis of the ADCs pipeline, based on several relevant parameters, such as [A] status of development, [B] target disease indication, [C] therapeutic area, [D] line of treatment, [E] dosing frequency, [F] type of therapy, [G] target antigen, [H] antibody isotype, [I] payload / cytotoxin / warhead, [J] type of payload and [K] type of linker.
  • Clinical Trial Analysis: An in-depth analysis of completed, ongoing, and planned clinical studies of various ADCs, based on several relevant parameters, such as [A] trial registration year, [B] number of patients enrolled, [C] trial phase, [D] trial status, [E] target patient population, [F] patient gender, [G] type of sponsor / collaborator, [H] study design, [I] most active player (based on the number of registered trials) and [J] geography.
  • Likely Partners Analysis: An in-depth analysis of ADC therapy developers that are likely to partner with ADC contract manufacturers, based on several relevant parameters, such as [A] developer strength, [B] pipeline strength and [C] maturity and [D] manufacturing capabilities.
  • Demand Analysis: An informed estimate of the annual commercial and clinical demand for ADC therapeutics (in kilograms) based on, based on relevant parameters, such as [A] target patient population, [B] dosing frequency and [C] dose strength of approved products and [D] clinical stage candidates.
  • Regional Capability Analysis: A detailed regional capability assessment framework, which compares the key geographies, based on a number of parameters, such as the [A] number of ADC contract manufacturers, [B] number of ADC manufacturing facilities, [C] number of facility expansions, [D] installed ADC bioconjugation capacity, [E] number of registered clinical trials and [F] demand for ADCs in that particular geographical region.
  • Attractiveness Competitiveness Matrix: A detailed assessment of the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments.
  • Market Impact Analysis: In-depth analysis of the factors that can impact the growth of the ADC contract manufacturing market. It also features identification and market analysis of [A] key drivers, [B] potential restraints, [C] emerging opportunities, and [D] existing challenges.

Key Questions Answered in this Report

  • How many companies are currently engaged in this market?
  • Which are the leading companies in this market?
  • What factors are likely to influence the evolution of this market?
  • What is the current and future market size?
  • What is the CAGR of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
  • Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

Additional Benefits

  • Complimentary Excel Data Packs for all Analytical Modules in the Report
  • 15% Free Content Customization
  • Detailed Report Walkthrough Session with Research Team
  • Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Introduction
  • 1.2. Market Share Insights
  • 1.3. Key Market Insights
  • 1.4. Report Coverage
  • 1.5. Key Questions Answered
  • 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
    • 2.2.1. Market Landscape and Market Trends
    • 2.2.2. Market Forecast and Opportunity Analysis
    • 2.2.3. Comparative Analysis
  • 2.3. Database Building
    • 2.3.1. Data Collection
    • 2.3.2. Data Validation
    • 2.3.3. Data Analysis
  • 2.4. Project Methodology
    • 2.4.1. Secondary Research
      • 2.4.1.1. Annual Reports
      • 2.4.1.2. Academic Research Papers
      • 2.4.1.3. Company Websites
      • 2.4.1.4. Investor Presentations
      • 2.4.1.5. Regulatory Filings
      • 2.4.1.6. White Papers
      • 2.4.1.7. Industry Publications
      • 2.4.1.8. Conferences and Seminars
      • 2.4.1.9. Government Portals
      • 2.4.1.10. Media and Press Releases
      • 2.4.1.11. Newsletters
      • 2.4.1.12. Industry Databases
      • 2.4.1.13. Roots Proprietary Databases
      • 2.4.1.14. Paid Databases and Sources
      • 2.4.1.15. Social Media Portals
      • 2.4.1.16. Other Secondary Sources
    • 2.4.2. Primary Research
      • 2.4.2.1. Types of Primary Research
        • 2.4.2.1.1. Qualitative Research
        • 2.4.2.1.2. Quantitative Research
        • 2.4.2.1.3. Hybrid Approach
      • 2.4.2.2. Advantages of Primary Research
      • 2.4.2.3. Techniques for Primary Research
        • 2.4.2.3.1. Interviews
        • 2.4.2.3.2. Surveys
        • 2.4.2.3.3. Focus Groups
        • 2.4.2.3.4. Observational Research
        • 2.4.2.3.5. Social Media Interactions
      • 2.4.2.4. Key Opinion Leaders Considered in Primary Research
        • 2.4.2.4.1. Company Executives (CXOs)
        • 2.4.2.4.2. Board of Directors
        • 2.4.2.4.3. Company Presidents and Vice Presidents
        • 2.4.2.4.4. Research and Development Heads
        • 2.4.2.4.5. Technical Experts
        • 2.4.2.4.6. Subject Matter Experts
        • 2.4.2.4.7. Scientists
        • 2.4.2.4.8. Doctors and Other Healthcare Providers
      • 2.4.2.5. Ethics and Integrity
        • 2.4.2.5.1. Research Ethics
        • 2.4.2.5.2. Data Integrity
    • 2.4.3. Analytical Tools and Databases
  • 2.5. Robust Quality Control

3. MARKET DYNAMICS

  • 3.1. Chapter Overview
  • 3.2. Forecast Methodology
    • 3.2.1. Top-down Approach
    • 3.2.2. Bottom-up Approach
    • 3.2.3. Hybrid Approach
  • 3.3. Market Assessment Framework
    • 3.3.1. Total Addressable Market (TAM)
    • 3.3.2. Serviceable Addressable Market (SAM)
    • 3.3.3. Serviceable Obtainable Market (SOM)
    • 3.3.4. Currently Acquired Market (CAM)
  • 3.4. Forecasting Tools and Techniques
    • 3.4.1. Qualitative Forecasting
    • 3.4.2. Correlation
    • 3.4.3. Regression
    • 3.4.4. Extrapolation
    • 3.4.5. Convergence
    • 3.4.6. Sensitivity Analysis
    • 3.4.7. Scenario Planning
    • 3.4.8. Data Visualization
    • 3.4.9. Time Series Analysis
    • 3.4.10. Forecast Error Analysis
  • 3.5. Key Considerations
    • 3.5.1. Demographics
    • 3.5.2. Government Regulations
    • 3.5.3. Reimbursement Scenarios
    • 3.5.4. Market Access
    • 3.5.5. Supply Chain
    • 3.5.6. Industry Consolidation
    • 3.5.7. Pandemic / Unforeseen Disruptions Impact
  • 3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

  • 4.1. Chapter Overview
  • 4.2. Market Dynamics
    • 4.2.1. Time Period
      • 4.2.1.1. Historical Trends
      • 4.2.1.2. Current and Forecasted Estimates
    • 4.2.2. Currency Coverage
      • 4.2.2.1. Major Currencies Affecting the Market
      • 4.2.2.2. Factors Affecting Currency Fluctuations on the Industry
      • 4.2.2.3. Impact of Currency Fluctuations on the Industry
    • 4.2.3. Foreign Currency Exchange Rate
      • 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
      • 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
    • 4.2.4. Recession
      • 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
      • 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
    • 4.2.5. Inflation
      • 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 4.2.5.2. Potential Impact of Inflation on the Market Evolution
    • 4.2.6. Interest Rates
      • 4.2.6.1. Interest Rates and Their Impact on the Market
      • 4.2.6.2. Strategies for Managing Interest Rate Risk
    • 4.2.7. Commodity Flow Analysis
      • 4.2.7.1. Type of Commodity
      • 4.2.7.2. Origins and Destinations
      • 4.2.7.3. Value and Weights
      • 4.2.7.4. Modes of Transportation
    • 4.2.8. Global Trade Dynamics
      • 4.2.8.1. Import Scenario
      • 4.2.8.2. Export Scenario
      • 4.2.8.3. Trade Policies
      • 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
      • 4.2.8.5. Impact of Trade Barriers on the Market
    • 4.2.9. War Impact Analysis
      • 4.2.9.1. Russian-Ukraine War
      • 4.2.9.2. Israel-Hamas War
    • 4.2.10. COVID Impact / Related Factors
      • 4.2.10.1. Global Economic Impact
      • 4.2.10.2. Industry-specific Impact
      • 4.2.10.3. Government Response and Stimulus Measures
      • 4.2.10.4. Future Outlook and Adaptation Strategies
    • 4.2.11. Other Indicators
      • 4.2.11.1. Fiscal Policy
      • 4.2.11.2. Consumer Spending
      • 4.2.11.3. Gross Domestic Product (GDP)
      • 4.2.11.4. Employment
      • 4.2.11.5. Taxes
      • 4.2.11.6. Stock Market Performance
      • 4.2.11.7. Cross-Border Dynamics
  • 4.3. Conclusion

5. EXECUTIVE SUMMARY

6. INTRODUCTION

  • 6.1. Chapter Overview
  • 6.2. Key Components of ADCs
    • 6.2.1. Antibody
    • 6.2.2. Cytotoxin (Payloads)
    • 6.2.3. Linker
  • 6.3. ADC Manufacturing
    • 6.3.1. Key Steps
    • 6.3.2. Technical Challenges
    • 6.3.3. Need for Outsourcing
  • 6.4. Challenges Associated with Supply Chain and Method Transfer
    • 6.4.1. Growing Demand for One-Stop-Shops and Integrated Service Providers
  • 6.5. Selecting a CMO Partner
  • 6.6. Future Perspective

7. MARKET LANDSCAPE

  • 7.1. Chapter Overview
  • 7.2. ADC Contract Manufacturers: Overall Market Landscape
    • 7.2.1. Analysis by Year of Establishment
    • 7.2.2. Analysis by Company Size
    • 7.2.3. Analysis by Location of Headquarters
    • 7.2.4. Analysis by Type of ADC Manufacturing Service Offered
    • 7.2.5. Analysis by Type of Additional Service Offered
    • 7.2.6. Analysis by Scale of Operation
    • 7.2.7. Analysis by Location of Manufacturing Facility

8. COMPANY COMPETITIVENESS ANALYSIS

  • 8.1. Chapter Overview
  • 8.2. Assumptions and Key Parameters
  • 8.3. Methodology
  • 8.4. ADC Contract Manufacturers: Company Competitiveness Analysis
    • 8.4.1. ADC Contract Manufacturers based in North America (Peer Group I)
    • 8.4.2. ADC Contract Manufacturers based in Europe (Peer Group II)
    • 8.4.3. ADC Contract Manufacturers based in Asia-Pacific (Peer Group III)
  • 8.5. Capability Benchmarking of top ADC Contract Manufacturers

9. COMPANY PROFILES: ADC CONTRACT MANUFACTURERS

  • 9.1. Chapter Overview
  • 9.2. MabPlex
    • 9.2.1. Company Overview
    • 9.2.2. ADC Related Services
    • 9.2.3. Manufacturing Facilities
    • 9.2.4. Recent Developments and Future Outlook
  • 9.3. Lonza
  • 9.4. Abzena
  • 9.5. GBI
  • 9.6. CARBOGEN AMICS
  • 9.7. Millipore Sigma
  • 9.8. WuXi Biologics
  • 9.9. Catalent Pharma Solutions
  • 9.10. Cerbios-Pharma
  • 9.11. Formosa Laboratories
  • 9.12. Sterling Pharma Solutions
  • 9.13. Piramal Pharma Solutions
  • 9.14. AbbVie Contract Manufacturing

10. RECENT EXPANSIONS

  • 10.1. Chapter Overview
  • 10.2. ADC Contract Manufacturers: Recent Expansions
    • 10.2.1. Analysis by Year of Expansion
    • 10.2.2. Analysis by Type of Expansion
    • 10.2.3. Analysis by Purpose of Expansion
    • 10.2.4. Analysis by Type of Facility
    • 10.2.5. Analysis by Scale of Operation
    • 10.2.6. Analysis by Location of Expanded Facility
    • 10.2.7. Most Active Players: Analysis by Number of Expansions

11. PARTNERSHIPS AND COLLABORATIONS

  • 11.1. Chapter Overview
  • 11.2. Partnership Models
  • 11.3. ADC Contract Manufacturers: Partnerships and Collaborations
    • 11.3.1. Analysis by Year of Partnership
    • 11.3.2. Analysis by Type of Partnership
    • 11.3.3. Analysis by Scale of Operation
    • 11.3.4. Most Active Players: Analysis by Number of Partnerships
    • 11.3.5. Analysis by Geography
      • 11.3.5.1. Intercontinental and Intracontinental Agreements
      • 11.3.5.2. Local and International Agreements

12. MAKE VERSUS BUY DECISION MAKING

  • 12.1. Chapter Overview
  • 12.2. Assumptions and Key Parameters
    • 12.2.1. Scenario 1
    • 12.2.2. Scenario 2
    • 12.2.3. Scenario 3
    • 12.2.4. Scenario 4
  • 12.3. Concluding Remarks

13. VALUE CHAIN ANALYSIS

  • 13.1. Chapter Overview
  • 13.2. ADC Development Value Chain
  • 13.3. Cost Distribution across the Value Chain
    • 13.3.1. Cost Associated with Antibody Manufacturing
    • 13.3.2. Cost Associated with Payload and Linker Manufacturing
    • 13.3.3. Cost Associated with Conjugation
    • 13.3.4. Cost Associated with Fill / Finish

14. CAPACITY ANALYSIS

  • 14.1. Chapter Overview
  • 14.2. Key Assumptions and Methodology
  • 14.3. ADC Manufacturing: Global Installed Capacity
    • 14.3.1. Analysis by Company Size
    • 14.3.2. Analysis by Location of Headquarters
    • 14.3.3. Analysis by Location of Manufacturing Facility
      • 14.3.3.1. Analysis by Region
      • 14.3.3.2. Analysis by Country
    • 14.3.4. Analysis by Key Players

15. CASE STUDY: ADC THERAPEUTICS MARKET OVERVIEW

  • 15.1. Chapter Overview
  • 15.2. ADC Therapeutics: Therapies Pipeline
    • 15.2.1. Analysis by Status of Development
    • 15.2.2. Analysis by Target Disease Indication
    • 15.2.3. Analysis by Therapeutic Area
    • 15.2.4. Analysis by Line of Treatment
    • 15.2.5. Analysis by Dosing Frequency
    • 15.2.6. Analysis by Type of Therapy
    • 15.2.7. Analysis by Target Antigen
    • 15.2.8. Analysis by Antibody Isotype
    • 15.2.9. Analysis by Payload / Cytotoxin / Warhead
    • 15.2.10. Analysis by Type of Payload
    • 15.2.11. Analysis by Linker
    • 15.2.12. Analysis by Type of Linker (Cleavable / Non-Cleavable)
  • 15.3. Antibody Drug Conjugates: Therapies to Watch
  • 15.4. Concluding Remarks

16. CLINICAL TRIAL ANALYSIS

  • 16.1. Chapter Overview
  • 16.2. Scope and Methodology
  • 16.3. Antibody Drug Conjugates: Clinical Trial Analysis
    • 16.3.1. Analysis by Trial Registration Year
    • 16.3.2. Analysis of Number of Patients Enrolled by Trial Registration Year
    • 16.3.3. Analysis by Trial Phase
    • 16.3.4. Analysis of Number of Patients Enrolled by Trial Phase
    • 16.3.5. Analysis by Trial Status
    • 16.3.6. Analysis by Trial Registration Year and Trial Status
    • 16.3.7. Analysis of Number of Patients Enrolled by Trial Status
    • 16.3.8. Analysis by Patient Gender
    • 16.3.9. Analysis by Study Design
      • 16.3.9.1. Analysis by Type of Allocation
      • 16.3.9.2. Analysis by Type of Intervention Model
      • 16.3.9.3. Analysis by Type of Masking
      • 16.3.9.4. Analysis by Trial Purpose
    • 16.3.10. Analysis by Type of Sponsor / Collaborator
    • 16.3.11. Leading Industry Players: Analysis by Number of Clinical Trials
    • 16.3.12. Leading Non-Industry Players: Analysis by Number of Clinical Trials
    • 16.3.13. Analysis by Geography
      • 16.3.13.1. Analysis of Clinical Trials by Geography
      • 16.3.13.2. Analysis of Clinical Trials by Geography and Trial Status
      • 16.3.13.3. Analysis of Patients Enrolled by Geography and Trial Status

17. LIKELY PARTNER ANALYSIS

  • 17.1. Chapter Overview
  • 17.2. Scoring Criteria and Key Assumptions
  • 17.3. Scope and Methodology
  • 17.4. Potential Strategic Partners based in North America
    • 17.4.1. Most Likely Partners
    • 17.4.2. Likely Partners
    • 17.4.3. Least Likely Partners
  • 17.5. Potential Strategic Partners based in Europe
    • 17.5.1. Most Likely Partners
    • 17.5.2. Likely Partners
    • 17.5.3. Least Likely Partners
  • 17.6. Potential Strategic Partners based in Asia-Pacific and Rest of the World
    • 17.6.1. Most Likely Partners
    • 17.6.2. Likely Partners
    • 17.6.3. Least Likely Partners

18. ADC THERAPEUTICS: DEMAND ANALYSIS

  • 18.1. Chapter Overview
  • 18.2. Key Assumptions and Methodology
  • 18.3. ADC Therapeutics: Global Annual Demand
    • 18.3.1. ADC Therapeutics: Annual Commercial Demand
      • 18.3.1.1. Analysis by Target Indication
      • 18.3.1.2. Analysis by Antibody Origin
      • 18.3.1.3. Analysis by Antibody Isotype
      • 18.3.1.4. Analysis by Type of Payload
      • 18.3.1.5. Analysis by Type of Linker
      • 18.3.1.6. Analysis by Key Geographical Regions
    • 18.3.2. ADC Therapeutics: Annual Clinical Demand
      • 18.3.2.1. Analysis by Phase of Development
      • 18.3.2.2. Analysis by Target Indication
      • 18.3.2.3. Analysis by Antibody Origin
      • 18.3.2.4. Analysis by Antibody Isotype
      • 18.3.2.5. Analysis by Type of Payload
      • 18.3.2.6. Analysis by Type of Linker
      • 18.3.2.7. Analysis by Key Geographical Regions

19. REGIONAL CAPABILITY ANALYSIS

  • 19.1. Chapter Overview
  • 19.2. Assumptions and Key Parameters
  • 19.3. ADC Contract Manufacturing Capabilities in North America
  • 19.4. ADC Contract Manufacturing Capabilities in Europe
  • 19.5. ADC Contract Manufacturing Capabilities in Asia-Pacific and Rest of the World

20. ATTRACTIVENESS COMPETITIVENESS MATRIX

  • 20.1. Chapter Overview
  • 20.2. AC Matrix: Overview
    • 20.2.1. Strong Business Segments
    • 20.2.2. Average Business Segments
    • 20.2.3. Weak Business Segments
  • 20.3. AC Matrix: Analytical Methodology
  • 20.4. AC Matrix: Overall ADC Contract Manufacturing Market Scenario
    • 20.4.1. AC Matrix: ADC Contract Manufacturing Scenario for Type of ADC Manufacturing Service Offered
    • 20.4.2. AC Matrix: ADC Contract Manufacturing Scenario for Key Geographical Regions

21. MARKET IMPACT ANALYSIS

  • 21.1. Chapter Overview
  • 21.2. Market Drivers
  • 21.3. Market Restraints
  • 21.4. Market Opportunities
  • 21.5. Market Challenges
  • 21.6. Conclusion

22. GLOBAL ADC CONTRACT MANUFACTURING MARKET

  • 22.1. Chapter Overview
  • 22.2. Key Assumptions and Methodology
  • 22.3. Global ADC Therapeutics Market: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 22.3.1. Scenario Analysis
      • 22.3.1.1. Conservative Scenario
      • 22.3.1.2. Optimistic Scenario
  • 22.4. Key Market Segmentations

23. ADC CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION

  • 23.1. Chapter Overview
  • 23.2. Key Assumptions and Methodology
  • 23.3. ADC Contract Manufacturing Market: Distribution by Scale of Operation
    • 23.3.1. ADC Contract Manufacturing Market for Clinical Scale, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 23.3.2. ADC Contract Manufacturing Market for Commercial Scale, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 23.4. Data Triangulation and Validation

24. ADC CONTRACT MANUFACTURING MARKET, BY PROCESS COMPONENT

  • 24.1. Chapter Overview
  • 24.2. Key Assumptions and Methodology
  • 24.3. ADC Contract Manufacturing Market: Distribution by Process Component
    • 24.3.1. ADC Contract Manufacturing Market for Antibodies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 24.3.2. ADC Contract Manufacturing Market for HPAPI / Cytotoxic Payloads, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 24.3.3. ADC Contract Manufacturing Market for Conjugation / Linkers, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 24.3.4. ADC Contract Manufacturing Market for Fill / Finish, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 24.4. Data Triangulation and Validation

25. ADC CONTRACT MANUFACTURING MARKET, BY TYPE OF PAYLOAD

  • 25.1. Chapter Overview
  • 25.2. Key Assumptions and Methodology
  • 25.3. ADC Contract Manufacturing Market: Distribution by Type of Payload
    • 25.3.1. ADC Contract Manufacturing Market for Tubulin Inhibitors, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 25.3.2. ADC Contract Manufacturing Market for Topoisomerase Inhibitors, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 25.3.3. ADC Contract Manufacturing Market for DNA Damaging Agents, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 25.3.4. ADC Contract Manufacturing Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 25.4. Data Triangulation and Validation

26. ADC CONTRACT MANUFACTURING MARKET, BY ANTIBODY ORIGIN

  • 26.1. Chapter Overview
  • 26.2. Key Assumptions and Methodology
  • 26.3. ADC Contract Manufacturing Market: Distribution by Antibody Origin
    • 26.3.1. ADC Contract Manufacturing Market for Humanized, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 26.3.2. ADC Contract Manufacturing Market for Chimeric, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 26.3.3. ADC Contract Manufacturing Market for Human, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 26.3.4. ADC Contract Manufacturing Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 26.4. Data Triangulation and Validation

27. ADC CONTRACT MANUFACTURING MARKET, BY ANTIBODY ISOTYPE

  • 27.1. Chapter Overview
  • 27.2. Key Assumptions and Methodology
  • 27.3. ADC Contract Manufacturing Market: Distribution by Antibody Isotype
    • 27.3.1. ADC Contract Manufacturing Market for IgG1, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 27.3.2. ADC Contract Manufacturing Market for IgG4, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 27.3.3. ADC Contract Manufacturing Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 27.4. Data Triangulation and Validation

28. ADC CONTRACT MANUFACTURING MARKET, BY TARGET INDICATION

  • 28.1. Chapter Overview
  • 28.2. Key Assumptions and Methodology
  • 28.3. ADC Contract Manufacturing Market: Distribution by Target Indication
    • 28.3.1. ADC Contract Manufacturing Market for Solid Tumors, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 28.3.2. ADC Contract Manufacturing Market for Hematological Malignancies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 28.4. Data Triangulation and Validation

29. ADC CONTRACT MANUFACTURING MARKET, BY TYPE OF LINKER

  • 29.1. Chapter Overview
  • 29.2. Key Assumptions and Methodology
  • 29.3. ADC Contract Manufacturing Market: Distribution by Type of Linker
    • 29.3.1. ADC Contract Manufacturing Market for Valine-citrulline, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 29.3.2. ADC Contract Manufacturing Market for SMCC, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 29.3.3. ADC Contract Manufacturing Market for Hydrazone, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 29.3.4. ADC Contract Manufacturing Market for Maleimide, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 29.3.5. ADC Contract Manufacturing Market for Maleimidocaproyl, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 29.3.6. ADC Contract Manufacturing Market for Tetrapeptide-based Linkers, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 29.3.7. ADC Contract Manufacturing Market for Peptide Linkers, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 29.3.8. ADC Contract Manufacturing Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 29.4. Data Triangulation and Validation

30. ADC CONTRACT MANUFACTURING MARKET, BY KEY GEOGRAPHICAL REGIONS

  • 30.1. Chapter Overview
  • 30.2. Key Assumptions and Methodology
  • 30.3. ADC Contract Manufacturing Market: Distribution by Key Geographical Regions
    • 30.3.1. ADC Contract Manufacturing Market in North America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
      • 30.3.1.1. ADC Contract Manufacturing Market in the US, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
      • 30.3.1.2. ADC Contract Manufacturing Market in Canada, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
      • 30.3.1.3. ADC Contract Manufacturing Market in Rest of North America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 30.3.2. ADC Contract Manufacturing Market in Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
      • 30.3.2.1. ADC Contract Manufacturing Market in the UK, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
      • 30.3.2.2. ADC Contract Manufacturing Market in Spain, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
      • 30.3.2.3. ADC Contract Manufacturing Market in Italy, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
      • 30.3.2.4. ADC Contract Manufacturing Market in Germany, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
      • 30.3.2.5. ADC Contract Manufacturing Market in France, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
      • 30.3.2.6. ADC Contract Manufacturing Market for Rest of Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
    • 30.3.3. ADC Contract Manufacturing Market in Asia-Pacific and Rest of the World, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
      • 30.3.3.1. ADC Contract Manufacturing Market in China, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
      • 30.3.3.2. ADC Contract Manufacturing Market in Japan, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
      • 30.3.3.3. ADC Contract Manufacturing Market in India, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
      • 30.3.3.4. ADC Contract Manufacturing Market in South Korea, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
      • 30.3.3.5. ADC Contract Manufacturing Market for Australia, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
      • 30.3.3.6. ADC Contract Manufacturing Market for Argentina, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
      • 30.3.3.7. ADC Contract Manufacturing Market for Brazil, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
      • 30.3.3.8. ADC Contract Manufacturing Market for Chile, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
      • 30.3.3.9. ADC Contract Manufacturing Market for Colombia, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
      • 30.3.3.10. ADC Contract Manufacturing Market for Israel, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
      • 30.3.3.11. ADC Contract Manufacturing Market for Kenya, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
      • 30.3.3.12. ADC Contract Manufacturing Market for Peru, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
      • 30.3.3.13. ADC Contract Manufacturing Market for South Africa, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
      • 30.3.3.14. ADC Contract Manufacturing Market for Turkey, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
      • 30.3.3.15. ADC Contract Manufacturing Market for Saudi Arabia, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
      • 30.3.3.16. ADC Contract Manufacturing Market for Other Countries, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  • 30.4. Data Triangulation and Validation

31. COMMERCIAL ADC CONTRACT MANUFACTURING MARKET

  • 31.1. Chapter Overview
  • 31.2. Key Assumptions and Methodology
  • 31.3. Commercial ADC Contract Manufacturing Market: Forecasted Estimates (Till 2035)
    • 31.3.1. Commercial ADC Contract Manufacturing Market: Distribution by Process Component, Forecasted Estimates (Till 2035)
    • 31.3.2. Commercial ADC Contract Manufacturing Market: Distribution by Type of Payload, Forecasted Estimates (Till 2035)
    • 31.3.3. Commercial ADC Contract Manufacturing Market: Distribution by Antibody Origin, Forecasted Estimates (Till 2035)
    • 31.3.4. Commercial ADC Contract Manufacturing Market: Distribution by Antibody Isotype, Forecasted Estimates (Till 2035)
    • 31.3.5. Commercial ADC Contract Manufacturing Market: Distribution by Target Indication, Forecasted Estimates (Till 2035)
    • 31.3.6. Commercial ADC Contract Manufacturing Market: Distribution by Type of Linker, Forecasted Estimates (Till 2035)
    • 31.3.7. Commercial ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, Forecasted Estimates (Till 2035)
  • 31.4. Data Triangulation and Validation

32. CLINICAL ADC CONTRACT MANUFACTURING MARKET

  • 32.1. Chapter Overview
  • 32.2. Key Assumptions and Methodology
  • 32.3. Clinical ADC Contract Manufacturing Market: Forecasted Estimates (Till 2035)
    • 32.3.1. Clinical ADC Contract Manufacturing Market: Distribution by Phase of Development, Forecasted Estimates (Till 2035)
    • 32.3.2. Clinical ADC Contract Manufacturing Market: Distribution by Process Component, Forecasted Estimates (Till 2035)
    • 32.3.3. Clinical ADC Contract Manufacturing Market: Distribution by Type of Payload, Forecasted Estimates (Till 2035)
    • 32.3.4. Clinical ADC Contract Manufacturing Market: Distribution by Antibody Origin, Forecasted Estimates (Till 2035)
    • 32.3.5. Clinical ADC Contract Manufacturing Market: Distribution by Antibody Isotype, Forecasted Estimates (Till 2035)
    • 32.3.6. Clinical ADC Contract Manufacturing Market: Distribution by Target Indication, Forecasted Estimates (Till 2035)
    • 32.3.7. Clinical ADC Contract Manufacturing Market: Distribution by Type of Linker, Forecasted Estimates (Till 2035)
    • 32.3.8. Clinical ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, Forecasted Estimates (Till 2035)
  • 32.4. Data Triangulation and Validation

33. CONCLUDING REMARKS

34. EXECUTIVE INSIGHTS

  • 34.1. Chapter Overview
  • 34.2. Company A
    • 34.2.1. Company Snapshot
    • 34.2.2. Interview Transcript: Business Development Manager
  • 34.3. Company B
    • 34.3.1. Company Snapshot
    • 34.3.2. Interview Transcript: Chief Executive Officer and Technical Business Development Manager
  • 34.4. Company C
    • 34.4.1. Company Snapshot
    • 34.4.2. Interview Transcript: Chief Commercial Officer
  • 34.5. Company D
    • 34.5.1. Company Snapshot
    • 34.5.2. Interview Transcript: Associate Scientist,
  • 34.6. Company E
    • 34.6.1. Company Snapshot
    • 34.6.2. Interview Transcript: Former Director Corporate Development
  • 34.7. Company F
    • 34.7.1. Company Snapshot
    • 34.7.2. Interview Transcript: Executive Director and Takashi Owa, Chief Innovation Officer
  • 34.8. Company G
    • 34.8.1. Company Snapshot
    • 34.8.2. Interview Transcript: Former Chief Business Officer
  • 34.9. Company H
    • 34.9.1. Company Snapshot
    • 34.9.2. Interview Transcript: Former Director of CDMO
  • 34.10. Company I
    • 34.10.1. Company Snapshot
    • 34.10.2. Interview Transcript: Director, Business Development
  • 34.11. Company J
    • 34.11.1. Company Snapshot
    • 34.11.2. Interview Transcript: Chief Executive Officer and Co-Founder
  • 34.12. Company K
    • 34.12.1. Company Snapshot
    • 34.12.2. Interview Transcript: Former Site Head
  • 34.13. Company L
    • 34.13.1. Company Snapshot
    • 34.13.2. Interview Transcript: Chief Executive Officer and Founder
  • 34.14. Company M
    • 34.14.1. Company Snapshot
    • 34.14.2. Interview Transcript: Former Chief Executive Officer
  • 34.15. Company N
    • 34.15.1. Company Snapshot
    • 34.15.2. Interview Transcript: Former Director, Business Development and Former Group Product Manager
  • 34.16. Company O
    • 34.16.1. Company Snapshot
    • 34.16.2. Interview Transcript: Former Head of Bioconjugates Commercial Development
  • 34.17. Company P
    • 34.17.1. Company Snapshot
    • 34.17.2. Interview Transcript: Senior Director, Commercial Development and Marketing Strategy Bioconjugates

35. APPENDIX I: TABULATED DATA

36. APPENDIX II: LIST OF COMPANIES AND ORGANIZATION

List of Tables

  • Table 6.1 Common Cytotoxins used for the Production of ADCs
  • Table 6.2 Safebridge Categorization / OEL Bands for Highly Potent / Cytotoxic Compounds
  • Table 7.1 ADC Contract Manufacturers: Information on Year of Establishment, Company Size, and Location of Headquarters
  • Table 7.2 ADC Contract Manufacturers: Information on Type of ADC Manufacturing Service Offered
  • Table 7.3 ADC Contract Manufacturers: Information on Type of Additional Service Offered and Scale of Operation
  • Table 7.4 ADC Contract Manufacturers: Information on Location of Manufacturing Facility
  • Table 9.1 ADC Contract Manufacturers: List of Companies Profiled
  • Table 9.2 MabPlex: Company Overview
  • Table 9.3 MabPlex: ADC Related Services
  • Table 9.4 MabPlex: Information on Manufacturing Facilities
  • Table 9.5 Lonza: Company Overview
  • Table 9.6 Lonza: ADC Related Services
  • Table 9.7 Lonza: Information on Manufacturing Facilities
  • Table 9.8 Lonza: Recent Developments and Future Outlook
  • Table 9.9 Abzena: Company Overview
  • Table 9.10 Abzena: ADC Related Services
  • Table 9.11 Abzena: Information on Manufacturing Facilities
  • Table 9.12 Abzena: Recent Developments and Future Outlook
  • Table 9.13 GBI: Company Overview
  • Table 9.14 GBI: ADC Related Services
  • Table 9.15 GBI: Information on Manufacturing Facilities
  • Table 9.16 CARBOGEN AMCIS: Company Overview
  • Table 9.17 CARBOGEN AMCIS: ADC Related Services
  • Table 9.18 CARBOGEN AMCIS: Information on Manufacturing Facilities
  • Table 9.19 CARBOGEN AMCIS: Recent Developments and Future Outlook
  • Table 9.20 Millipore Sigma: Company Overview
  • Table 9.21 Millipore Sigma: ADC Related Services
  • Table 9.22 Millipore Sigma: Information on Manufacturing Facilities
  • Table 9.23 WuXi Biologics: Company Overview
  • Table 9.24 WuXi Biologics: ADC Related Services
  • Table 9.25 WuXi Biologics: Information on Manufacturing Facilities
  • Table 9.26 WuXi Biologics: Recent Developments and Future Outlook
  • Table 9.27 Catalent Pharma Solutions: Company Overview
  • Table 9.28 Catalent Pharma Solutions: ADC Related Services
  • Table 9.29 Catalent Pharma Solutions: Information on Manufacturing Facilities
  • Table 9.30 Catalent Pharma Solutions: Recent Developments and Future Outlook
  • Table 9.31 Cerbios-Pharma: Company Overview
  • Table 9.32 Cerbios-Pharma: ADC Related Services
  • Table 9.33 Cerbios-Pharma: Information on Manufacturing Facilities
  • Table 9.34 Cerbios-Pharma: Recent Developments and Future Outlook
  • Table 9.35 Formosa Laboratories: Company Overview
  • Table 9.36 Formosa Laboratories: ADC Related Services
  • Table 9.37 Formosa Laboratories: Information on Manufacturing Facilities
  • Table 9.38 Sterling Pharma Solutions: Company Overview
  • Table 9.39 Sterling Pharma Solutions: ADC Related Services
  • Table 9.40 Sterling Pharma Solutions: Information on Manufacturing Facilities
  • Table 9.41 Sterling Pharma Solutions: Recent Developments and Future Outlook
  • Table 9.42 Piramal Pharma Solutions: Company Overview
  • Table 9.43 Piramal Pharma Solutions: ADC Related Services
  • Table 9.44 Piramal Pharma Solutions: Information on Manufacturing Facilities
  • Table 9.45 Piramal Pharma Solutions: Recent Developments and Future Outlook
  • Table 9.46 AbbVie Contract Manufacturing: Company Overview
  • Table 9.47 AbbVie Contract Manufacturing: ADC Related Services
  • Table 9.48 AbbVie Contract Manufacturing: Information on Manufacturing Facilities
  • Table 10.1 ADC Contract Manufacturers: Information on Year of Expansion, Type of Expansion, Purpose of Expansion, and Type of Facility, Since 2019
  • Table 10.2 ADC Contract Manufacturers: Information on Location of Expanded Facility and Scale of Operation
  • Table 11.1 ADC Contract Manufacturers: Information on Year of Partnership, Type of Partnership, and Scale of Operation, Since 2020
  • Table 13.1 ADC Components: Information on Cost of Cytotoxins
  • Table 13.2 ADC Components: Information on Cost of Linkers
  • Table 14.1 Global Installed ADC Contract Manufacturing Capacity: Sample Data Set (Yield)
  • Table 14.2 Global Installed ADC Contract Manufacturing Capacity: Sample Data Set (Average Capacity)
  • Table 14.3 Global Installed ADC Manufacturing Capacity: Information on Total Capacity based on Company Size
  • Table 15.1 ADC Therapeutics: Information on Drug Candidates, Developers, Status of Development, Target Disease Indication and Therapeutic Area
  • Table 15.2 ADC Therapeutics to Watch: Information on Drug Candidates, Developer, Status of Development, Target Disease Indication and Therapeutic Area
  • Table 17.1 Most Likely Partners based in North America
  • Table 17.2 Likely Partners based in North America
  • Table 17.3 Least Likely Partners based in North America
  • Table 17.4 Most Likely Partners based in Europe
  • Table 17.5 Likely Partners based in Europe
  • Table 17.6 Least Likely Partners based in Europe
  • Table 17.7 Most Likely Partners based in Asia-Pacific and Rest of the World
  • Table 17.8 Likely Partners based in Asia-Pacific and Rest of the World
  • Table 17.9 Least Likely Partners based in Asia-Pacific and Rest of the World
  • Table 18.1 List of Late Stage ADCs
  • Table 34.1 Cerbios-Pharma: Key Highlights
  • Table 34.2 BSP Biopharmaceuticals: Key Highlights
  • Table 34.3 Cerbios-Pharma: Key Highlights
  • Table 34.4 Ajinomoto Bio-Pharma Services: Key Highlights
  • Table 34.5 GBI: Key Highlights
  • Table 34.6 Eisai: Key Highlights
  • Table 34.7 NBE-Therapeutics: Key Highlights
  • Table 34.8 Pierre Fabre: Key Highlights
  • Table 34.9 Synaffix: Key Highlights
  • Table 6.3 Common Cytotoxins used for the Production of ADCs
  • Table 6.4 Safebridge Categorization / OEL Bands for Highly Potent / Cytotoxic Compounds
  • Table 7.5 ADC Contract Manufacturers: Information on Year of Establishment, Company Size, and Location of Headquarters
  • Table 7.6 ADC Contract Manufacturers: Information on Type of ADC Manufacturing Service Offered
  • Table 7.7 ADC Contract Manufacturers: Information on Type of Additional Service Offered and Scale of Operation
  • Table 7.8 ADC Contract Manufacturers: Information on Location of Manufacturing Facility
  • Table 9.49 ADC Contract Manufacturers: List of Companies Profiled
  • Table 9.50 MabPlex: Company Overview
  • Table 9.51 MabPlex: ADC Related Services
  • Table 9.52 MabPlex: Information on Manufacturing Facilities
  • Table 9.53 Lonza: Company Overview
  • Table 9.54 Lonza: ADC Related Services
  • Table 9.55 Lonza: Information on Manufacturing Facilities
  • Table 9.56 Lonza: Recent Developments and Future Outlook
  • Table 9.57 Abzena: Company Overview
  • Table 9.58 Abzena: ADC Related Services
  • Table 9.59 Abzena: Information on Manufacturing Facilities
  • Table 9.60 Abzena: Recent Developments and Future Outlook
  • Table 9.61 GBI: Company Overview
  • Table 9.62 GBI: ADC Related Services
  • Table 9.63 GBI: Information on Manufacturing Facilities
  • Table 9.64 CARBOGEN AMCIS: Company Overview
  • Table 9.65 CARBOGEN AMCIS: ADC Related Services
  • Table 9.66 CARBOGEN AMCIS: Information on Manufacturing Facilities
  • Table 9.67 CARBOGEN AMCIS: Recent Developments and Future Outlook
  • Table 9.68 Millipore Sigma: Company Overview
  • Table 9.69 Millipore Sigma: ADC Related Services
  • Table 9.70 Millipore Sigma: Information on Manufacturing Facilities
  • Table 9.71 WuXi Biologics: Company Overview
  • Table 9.72 WuXi Biologics: ADC Related Services
  • Table 9.73 WuXi Biologics: Information on Manufacturing Facilities
  • Table 9.74 WuXi Biologics: Recent Developments and Future Outlook
  • Table 9.75 Catalent Pharma Solutions: Company Overview
  • Table 9.76 Catalent Pharma Solutions: ADC Related Services
  • Table 9.77 Catalent Pharma Solutions: Information on Manufacturing Facilities
  • Table 9.78 Catalent Pharma Solutions: Recent Developments and Future Outlook
  • Table 9.79 Cerbios-Pharma: Company Overview
  • Table 9.80 Cerbios-Pharma: ADC Related Services
  • Table 9.81 Cerbios-Pharma: Information on Manufacturing Facilities
  • Table 9.82 Cerbios-Pharma: Recent Developments and Future Outlook
  • Table 9.83 Formosa Laboratories: Company Overview
  • Table 9.84 Formosa Laboratories: ADC Related Services
  • Table 9.85 Formosa Laboratories: Information on Manufacturing Facilities
  • Table 9.86 Sterling Pharma Solutions: Company Overview
  • Table 9.87 Sterling Pharma Solutions: ADC Related Services
  • Table 9.88 Sterling Pharma Solutions: Information on Manufacturing Facilities
  • Table 9.89 Sterling Pharma Solutions: Recent Developments and Future Outlook
  • Table 9.90 Piramal Pharma Solutions: Company Overview
  • Table 9.91 Piramal Pharma Solutions: ADC Related Services
  • Table 9.92 Piramal Pharma Solutions: Information on Manufacturing Facilities
  • Table 9.93 Piramal Pharma Solutions: Recent Developments and Future Outlook
  • Table 9.94 AbbVie Contract Manufacturing: Company Overview
  • Table 9.95 AbbVie Contract Manufacturing: ADC Related Services
  • Table 9.96 AbbVie Contract Manufacturing: Information on Manufacturing Facilities
  • Table 10.3 ADC Contract Manufacturers: Information on Year of Expansion, Type of Expansion, Purpose of Expansion, and Type of Facility, Since 2019
  • Table 10.4 ADC Contract Manufacturers: Information on Location of Expanded Facility and Scale of Operation
  • Table 11.2 ADC Contract Manufacturers: Information on Year of Partnership, Type of Partnership, and Scale of Operation, Since 2020
  • Table 13.3 ADC Components: Information on Cost of Cytotoxins
  • Table 13.4 ADC Components: Information on Cost of Linkers
  • Table 14.4 Global Installed ADC Contract Manufacturing Capacity: Sample Data Set (Yield)
  • Table 14.5 Global Installed ADC Contract Manufacturing Capacity: Sample Data Set (Average Capacity)
  • Table 14.6 Global Installed ADC Manufacturing Capacity: Information on Total Capacity based on Company Size
  • Table 15.3 ADC Therapeutics: Information on Drug Candidates, Developers, Status of Development, Target Disease Indication and Therapeutic Area
  • Table 15.4 ADC Therapeutics to Watch: Information on Drug Candidates, Developer, Status of Development, Target Disease Indication and Therapeutic Area
  • Table 17.10 Most Likely Partners based in North America
  • Table 17.11 Likely Partners based in North America
  • Table 17.12 Least Likely Partners based in North America
  • Table 17.13 Most Likely Partners based in Europe
  • Table 17.14 Likely Partners based in Europe
  • Table 17.15 Least Likely Partners based in Europe
  • Table 17.16 Most Likely Partners based in Asia-Pacific and Rest of the World
  • Table 17.17 Likely Partners based in Asia-Pacific and Rest of the World
  • Table 17.18 Least Likely Partners based in Asia-Pacific and Rest of the World
  • Table 18.2 List of Late Stage ADCs
  • Table 34.10 Cerbios-Pharma: Key Highlights
  • Table 34.11 BSP Biopharmaceuticals: Key Highlights
  • Table 34.12 Cerbios-Pharma: Key Highlights
  • Table 34.13 Ajinomoto Bio-Pharma Services: Key Highlights
  • Table 34.14 GBI: Key Highlights
  • Table 34.15 Eisai: Key Highlights
  • Table 34.16 NBE-Therapeutics: Key Highlights
  • Table 34.17 Pierre Fabre: Key Highlights
  • Table 34.18 Synaffix: Key Highlights
  • Table 34.19 Syndivia: Key Highlights
  • Table 34.20 Piramal Pharma Solutions: Key Highlights
  • Table 34.21 Oxford BioTherapeutics: Key Highlights
  • Table 34.22 Abzena: Key Highlights
  • Table 34.23 Catalent Pharma Solutions: Key Highlights
  • Table 34.24 Lonza: Key Highlights
  • Table 34.25 Lonza: Key Highlights
  • Table 35.1 ADC Contract Manufacturers: Distribution by Year of Establishment
  • Table 35.2 ADC Contract Manufacturers: Distribution by Company Size
  • Table 35.3 ADC Contract Manufacturers: Distribution by Location of Headquarters
  • Table 35.4 ADC Contract Manufacturers: Distribution by Type of ADC Manufacturing Service Offered
  • Table 35.5 ADC Contract Manufacturers: Distribution by Type of Additional Service Offered
  • Table 35.6 ADC Contract Manufacturers: Distribution by Scale of Operation
  • Table 35.7 ADC Contract Manufacturers: Distribution by Location of Manufacturing Facility
  • Table 35.8 Lonza: Annual Revenues, (YEN Billion), Since 2021
  • Table 35.9 WuXi Biologics: Annual Revenues, (CHF Billion), Since 2021
  • Table 35.10 Catalent Pharma Solutions: Annual Revenues, (USD Billion), Since 2021
  • Table 35.11 Recent Expansions: Distribution by Year of Expansion
  • Table 35.12 Recent Expansions: Distribution by Type of Expansion
  • Table 35.13 Recent Expansions: Distribution by Purpose of Expansion
  • Table 35.14 Recent Expansions: Distribution by Type of Facility
  • Table 35.15 Recent Expansions: Distribution by Scale of Operation
  • Table 35.16 Recent Expansions: Distribution by Location of Expanded Facility
  • Table 35.17 Most Active Players: Distribution by Number of Expansion Initiatives
  • Table 35.18 Partnerships and Collaborations: Distribution by Year of Partnership
  • Table 35.19 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 35.20 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Table 35.21 Partnerships and Collaborations: Distribution by Purpose of Partnership
  • Table 35.22 Partnerships and Collaborations: Distribution by Scale of Operation
  • Table 35.23 Most Active Players: Distribution by Number of Partnerships
  • Table 35.24 Global Installed ADC Manufacturing Capacity: Distribution by Company Size
  • Table 35.25 Global Installed ADC Manufacturing Capacity: Distribution by Location of Headquarters
  • Table 35.26 Global Installed ADC Manufacturing Capacity: Distribution by Location of Manufacturing Facility (Region)
  • Table 35.27 Global Installed ADC Manufacturing Capacity: Distribution by Location of Manufacturing Facility (Country)
  • Table 35.28 Global Installed ADC Manufacturing Capacity: Distribution by Key Players
  • Table 35.29 ADC Therapeutics: Distribution by Status of Development
  • Table 35.30 ADC Therapeutics: Distribution by Target Disease Indication
  • Table 35.31 ADC Therapeutics: Distribution by Therapeutic Area
  • Table 35.32 ADC Therapeutics: Distribution by Line of Treatment
  • Table 35.33 ADC Therapeutics: Distribution by Dosing Frequency
  • Table 35.34 ADC Therapeutics: Distribution by Type of Therapy
  • Table 35.35 ADC Therapeutics: Distribution by Target Antigen
  • Table 35.36 ADC Therapeutics: Distribution by Antibody Isotype
  • Table 35.37 ADC Therapeutics: Distribution by Payload / Cytotoxin / Warhead
  • Table 35.38 ADC Therapeutics: Distribution by Type of Payload
  • Table 35.39 ADC Therapeutics: Distribution by Linker
  • Table 35.40 ADC Therapeutics: Distribution by Type of Linker
  • Table 35.41 Clinical Trial Analysis: Cumulative Year-wise Trend, Since 2021
  • Table 35.42 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Registration Year, Since 2021
  • Table 35.43 Clinical Trial Analysis: Distribution by Trial Phase
  • Table 35.44 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Phase
  • Table 35.45 Clinical Trial Analysis: Distribution by Trial Status
  • Table 35.46 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Since 2021
  • Table 35.47 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Status
  • Table 35.48 Clinical Trial Analysis: Distribution by Patient Gender
  • Table 35.49 Clinical Trial Analysis: Distribution by Type of Allocation
  • Table 35.50 Clinical Trial Analysis: Distribution by Type of Intervention Model
  • Table 35.51 Clinical Trial Analysis: Distribution by Type of Masking
  • Table 35.52 Clinical Trial Analysis: Distribution by Trial Purpose
  • Table 35.53 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Table 35.54 Leading Industry Players: Distribution by Number of Clinical Trials
  • Table 35.55 Leading Non-Industry Players: Distribution by Number of Clinical Trials
  • Table 35.56 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
  • Table 35.57 Clinical Trial Analysis: Distribution of Clinical Trials by Geography and Trial Status
  • Table 35.58 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography and Trial Status
  • Table 35.59 Global Demand for ADC Therapeutics, till 2035 (in kg)
  • Table 35.60 Global Demand for ADC Therapeutics: Distribution by Stage of Development, till 2035 (in kg)
  • Table 35.61 Global Commercial Demand for ADC Therapeutics, till 2035 (in kg)
  • Table 35.62 Global Commercial Demand for ADC Therapeutics: Distribution by Target Indication, till 2035 (in kg)
  • Table 35.63 Global Commercial Demand for ADC Therapeutics: Distribution by Antibody Origin, till 2035 (in kg)
  • Table 35.64 Global Commercial Demand for ADC Therapeutics: Distribution by Antibody Isotype, till 2035 (in kg)
  • Table 35.65 Global Commercial Demand for ADC Therapeutics: Distribution by Type of Payload, till 2035 (in kg)
  • Table 35.66 Global Commercial Demand for ADC Therapeutics: Distribution by Type of Linker, till 2035 (in kg)
  • Table 35.67 Global Commercial Demand for ADC Therapeutics: Distribution by Key Geographical Regions, till 2035 (in kg)
  • Table 35.68 Global Clinical Demand for ADC Therapeutics, till 2035 (in kg)
  • Table 35.69 Global Clinical Demand for ADC Therapeutics: Distribution by Phase of Development, till 2035 (in kg)
  • Table 35.70 Global Clinical Demand for ADC Therapeutics: Distribution by Target Indication, till 2035 (in kg)
  • Table 35.71 Global Clinical Demand for ADC Therapeutics: Distribution by Antibody Origin, till 2035 (in kg)
  • Table 35.72 Global Clinical Demand for ADC Therapeutics: Distribution by Antibody Isotype, till 2035 (in kg)
  • Table 35.73 Global Clinical Demand for ADC Therapeutics: Distribution by Type of Payload, till 2035 (in kg)
  • Table 35.74 Global Clinical Demand for ADC Therapeutics: Distribution by Type of Linker, till 2035 (in kg)
  • Table 35.75 Global Clinical Demand for ADC Therapeutics: Distribution by Key Geographical Regions, till 2035 (in kg)
  • Table 35.76 Regional Capability Analysis: ADC Contract Manufacturing Capabilities in North America
  • Table 35.77 Regional Capability Analysis: ADC Contract Manufacturing Capabilities in Europe
  • Table 35.78 Regional Capability Analysis: ADC Contract Manufacturing Capabilities in Asia-Pacific and Rest of the World
  • Table 35.79 Global ADC Contract Manufacturing Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035): Base Scenario (USD Billion)
  • Table 35.80 Global ADC Contract Manufacturing Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035): Conservative Scenario (USD Billion)
  • Table 35.81 Global ADC Contract Manufacturing Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035): Optimistic Scenario (USD Billion)
  • Table 35.82 Global ADC Contract Manufacturing Market: Distribution by Scale of Operation
  • Table 35.83 ADC Contract Manufacturing Market for Clinical Scale: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.84 ADC Contract Manufacturing Market for Commercial Scale: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.85 ADC Contract Manufacturing Market: Distribution by Process Component
  • Table 35.86 ADC Contract Manufacturing Market for Antibodies: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.87 ADC Contract Manufacturing Market for HPAPI / Cytotoxic Payloads: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.88 ADC Contract Manufacturing Market for Conjugation / Linkers: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.89 ADC Contract Manufacturing Market for Fill / Finish: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.90 ADC Contract Manufacturing Market: Distribution by Type of Payload
  • Table 35.91 ADC Contract Manufacturing Market for Tubulin Inhibitors: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.92 ADC Contract Manufacturing Market for Topoisomerase Inhibitors: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.93 ADC Contract Manufacturing Market for DNA Damaging Agents: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.94 ADC Contract Manufacturing Market for Others: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.95 ADC Contract Manufacturing Market: Distribution by Antibody Origin
  • Table 35.96 ADC Contract Manufacturing Market for Humanized: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.97 ADC Contract Manufacturing Market for Chimeric: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.98 ADC Contract Manufacturing Market for Human: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.99 ADC Contract Manufacturing Market for Others: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.100 ADC Contract Manufacturing Market: Distribution by Antibody Isotype
  • Table 35.101 ADC Contract Manufacturing Market for IgG1: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.102 ADC Contract Manufacturing Market for IgG4: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.103 ADC Contract Manufacturing Market for Others: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.104 ADC Contract Manufacturing Market: Distribution by Target Indication
  • Table 35.105 ADC Contract Manufacturing Market for Solid Tumors: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.106 ADC Contract Manufacturing Market for Hematological Malignancies: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.107 ADC Contract Manufacturing Market: Distribution by Type of Linker
  • Table 35.108 ADC Contract Manufacturing Market for Valine-citrulline: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.109 ADC Contract Manufacturing Market for SMCC: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.110 ADC Contract Manufacturing Market for Hydrazone SMCC: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.111 ADC Contract Manufacturing Market for Maleimide: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.112 ADC Contract Manufacturing Market for Maleimidocaproyl: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.113 ADC Contract Manufacturing Market for Tetrapeptide-based Linkers: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.114 ADC Contract Manufacturing Market for Peptide Linkers: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.115 ADC Contract Manufacturing Market for Others: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.116 ADC Contract Manufacturing Market: Distribution by Key Geographical Regions
  • Table 35.117 ADC Contract Manufacturing Market in North America: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.118 ADC Contract Manufacturing Market in the US: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.119 ADC Contract Manufacturing Market in Canada: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.120 ADC Contract Manufacturing Market in Rest of North America: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.121 ADC Contract Manufacturing Market in Europe: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.122 ADC Contract Manufacturing Market in the UK: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.123 ADC Contract Manufacturing Market in Spain: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.124 ADC Contract Manufacturing Market in Italy: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.125 ADC Contract Manufacturing Market in Germany: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.126 ADC Contract Manufacturing Market in France: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.127 ADC Contract Manufacturing Market in Rest of Europe: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.128 ADC Contract Manufacturing Market in Asia-Pacific and Rest of the World: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.129 ADC Contract Manufacturing Market in China: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.130 ADC Contract Manufacturing Market in Japan: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.131 ADC Contract Manufacturing Market in India: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.132 ADC Contract Manufacturing Market in South Korea: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.133 ADC Contract Manufacturing Market in Australia: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.134 ADC Contract Manufacturing Market in Argentina: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.135 ADC Contract Manufacturing Market in Brazil: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.136 ADC Contract Manufacturing Market in Chile: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.137 ADC Contract Manufacturing Market in Colombia: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.138 ADC Contract Manufacturing Market in Israel: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.139 ADC Contract Manufacturing Market in Kenya: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.140 ADC Contract Manufacturing Market in Peru: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.141 ADC Contract Manufacturing Market in South Africa: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.142 ADC Contract Manufacturing Market in Turkey: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.143 ADC Contract Manufacturing Market in Saudi Arabia: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.144 ADC Contract Manufacturing Market in Other Countries: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Table 35.145 Commercial ADC Contract Manufacturing Market, Forecasted Estimates, till 2035 (USD Million)
  • Table 35.146 Commercial ADC Contract Manufacturing Market: Distribution by Process Component, Forecasted Estimates, till 2035 (USD Million)
  • Table 35.147 Commercial ADC Contract Manufacturing Market: Distribution by Type of Payload, Forecasted Estimates, till 2035 (USD Million)
  • Table 35.148 Commercial ADC Contract Manufacturing Market: Distribution by Antibody Origin, Forecasted Estimates, till 2035 (USD Million)
  • Table 35.149 Commercial ADC Contract Manufacturing Market: Distribution by Antibody Isotype, Forecasted Estimates, till 2035 (USD Million)
  • Table 35.150 Commercial ADC Contract Manufacturing Market: Distribution by Target Indication, Forecasted Estimates, till 2035 (USD Million)
  • Table 35.151 Commercial ADC Contract Manufacturing Market: Distribution by Type of Linker, Forecasted Estimates, till 2035 (USD Million)
  • Table 35.152 Commercial ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, Forecasted Estimates, till 2035 (USD Million)
  • Table 35.153 Clinical ADC Contract Manufacturing Market, Forecasted Estimates, till 2035 (USD Million)
  • Table 35.154 Clinical ADC Contract Manufacturing Market: Distribution by Phase of Development, Forecasted Estimates, till 2035 (USD Million)
  • Table 35.155 Clinical ADC Contract Manufacturing Market: Distribution by Process Component, Forecasted Estimates, till 2035 (USD Million)
  • Table 35.156 Clinical ADC Contract Manufacturing Market: Distribution by Type of Payload, Forecasted Estimates, till 2035 (USD Million)
  • Table 35.157 Clinical ADC Contract Manufacturing Market: Distribution by Antibody Origin, Forecasted Estimates, till 2035 (USD Million)
  • Table 35.158 Clinical ADC Contract Manufacturing Market: Distribution by Antibody Isotype, Forecasted Estimates, till 2035 (USD Million)
  • Table 35.159 Clinical ADC Contract Manufacturing Market: Distribution by Target Indication, Forecasted Estimates, till 2035 (USD Million)
  • Table 35.160 Clinical ADC Contract Manufacturing Market: Distribution by Type of Linker, Forecasted Estimates, till 2035 (USD Million)
  • Table 35.161 Clinical ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, Forecasted Estimates, till 2035 (USD Million)

List of Figures

  • Figure 2.1 Research Methodology: Project Methodology
  • Figure 2.2 Research Methodology: Data Sources for Secondary Research
  • Figure 2.3 Research Methodology: Robust Quality Control
  • Figure 3.1 Market Dynamics: Forecast Methodology
  • Figure 3.2 Market Dynamics: Market Assessment Framework
  • Figure 4.1 Lessons Learnt from Past Recessions
  • Figure 5.1 Executive Summary: Market Landscape
  • Figure 5.2 Executive Summary: Market Trends
  • Figure 5.3 Executive Summary: Capacity and Demand Analysis
  • Figure 5.4 Executive Summary: Market Forecast and Opportunity Analysis
  • Figure 6.1 Key Components of an ADC
  • Figure 6.2 ADC Manufacturing Steps
  • Figure 6.3 Key Parameters while Selecting a CMO Partner
  • Figure 7.1 ADC Contract Manufacturers: Distribution by Year of Establishment
  • Figure 7.2 ADC Contract Manufacturers: Distribution by Company Size
  • Figure 7.3 ADC Contract Manufacturers: Distribution by Location of Headquarters
  • Figure 7.4 ADC Contract Manufacturers: Distribution by Type of ADC Manufacturing Service Offered
  • Figure 7.5 ADC Contract Manufacturers: Distribution by Type of Additional Service Offered
  • Figure 7.6 ADC Contract Manufacturers: Distribution by Scale of Operation
  • Figure 7.7 ADC Contract Manufacturers: Distribution by Location of Manufacturing Facility
  • Figure 8.1 Company Competitiveness Analysis: Overview of Peer Group I
  • Figure 8.2 Company Competitiveness Analysis: Overview of Peer Group II
  • Figure 8.3 Company Competitiveness Analysis: Overview of Peer Group III
  • Figure 8.4 Company Competitiveness Analysis: ADC Contract Manufacturing Services Offered by Companies based in North America
  • Figure 8.5 Company Competitiveness Analysis: ADC Contract Manufacturing Services Offered by Companies based in Europe
  • Figure 8.6 Company Competitiveness Analysis: ADC Contract Manufacturing Services Offered by Companies based in Asia-Pacific
  • Figure 9.1 Lonza: Annual Revenues, (YEN Billion), Since 2021
  • Figure 9.2 WuXi Biologics: Annual Revenues, (CHF Billion), Since 2021
  • Figure 9.3 Catalent Pharma Solutions: Annual Revenues, (USD Billion), Since 2021
  • Figure 10.1 Recent Expansions: Distribution by Year of Expansion
  • Figure 10.2 Recent Expansions: Distribution by Type of Expansion
  • Figure 10.3 Recent Expansions: Distribution by Purpose of Expansion
  • Figure 10.4 Recent Expansions: Distribution by Type of Facility
  • Figure 10.5 Recent Expansions: Distribution by Scale of Operation
  • Figure 10.6 Recent Expansions: Distribution by Location of Expanded Facility
  • Figure 10.7 Most Active Players: Distribution by Number of Expansion Initiatives
  • Figure 11.1 Partnerships and Collaborations: Distribution by Year of Partnership
  • Figure 11.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 11.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
  • Figure 11.4 Partnerships and Collaborations: Distribution by Purpose of Partnership
  • Figure 11.5 Partnerships and Collaborations: Distribution by Scale of Operation
  • Figure 11.6 Most Active Players: Distribution by Number of Partnerships
  • Figure 11.7 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Figure 11.8 Partnerships and Collaborations: Local and International Agreements
  • Figure 12.1 Make versus Buy Decision Making Framework
  • Figure 12.2 Make versus Buy Decision Making: Possible Scenario Descriptions
  • Figure 13.1 Value Chain Analysis: ADC Development Overview
  • Figure 13.2 Value Chain Analysis: ADC Contract Manufacturing Overview
  • Figure 13.3 ADC Therapeutics: Distribution by Cost of Raw Material Required for Clinical Stage Manufacturing
  • Figure 13.4 Value Chain Analysis: Distribution by Cost
  • Figure 13.5 Costs Associated with Antibody Manufacturing
  • Figure 13.6 Costs Associated with Payload and Linker Manufacturing
  • Figure 13.7 Costs Associated with Conjugation
  • Figure 13.8 Costs Associated with Fill / Finish
  • Figure 14.1 Global Installed ADC Manufacturing Capacity: Distribution by Company Size
  • Figure 14.2 Global Installed ADC Manufacturing Capacity: Distribution by Location of Headquarters
  • Figure 14.3 Global Installed ADC Manufacturing Capacity: Distribution by Location of Manufacturing Facility (Region)
  • Figure 14.4 Global Installed ADC Manufacturing Capacity: Distribution by Location of Manufacturing Facility (Country)
  • Figure 14.5 Global Installed ADC Manufacturing Capacity: Distribution by Key Players
  • Figure 15.1 ADC Therapeutics: Distribution by Status of Development
  • Figure 15.2 ADC Therapeutics: Distribution by Target Disease Indication
  • Figure 15.3 ADC Therapeutics: Distribution by Therapeutic Area
  • Figure 15.4 ADC Therapeutics: Distribution by Line of Treatment
  • Figure 15.5 ADC Therapeutics: Distribution by Dosing Frequency
  • Figure 15.6 ADC Therapeutics: Distribution by Type of Therapy
  • Figure 15.7 ADC Therapeutics: Distribution by Target Antigen
  • Figure 15.8 ADC Therapeutics: Distribution by Antibody Isotype
  • Figure 15.9 ADC Therapeutics: Distribution by Payload / Cytotoxin / Warhead
  • Figure 15.10 ADC Therapeutics: Distribution by Type of Payload
  • Figure 15.11 ADC Therapeutics: Distribution by Linker
  • Figure 15.12 ADC Therapeutics: Distribution by Type of Linker
  • Figure 16.1 Clinical Trial Analysis: Cumulative Year-wise Trend, Since 2021
  • Figure 16.2 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Registration Year, Since 2021
  • Figure 16.3 Clinical Trial Analysis: Distribution by Trial Phase
  • Figure 16.4 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Phase
  • Figure 16.5 Clinical Trial Analysis: Distribution by Trial Status
  • Figure 16.6 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Since 2021
  • Figure 16.7 Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Status
  • Figure 16.8 Clinical Trial Analysis: Distribution by Patient Gender
  • Figure 16.9 Clinical Trial Analysis: Distribution by Type of Allocation
  • Figure 16.10 Clinical Trial Analysis: Distribution by Type of Intervention Model
  • Figure 16.11 Clinical Trial Analysis: Distribution by Type of Masking
  • Figure 16.12 Clinical Trial Analysis: Distribution by Trial Purpose
  • Figure 16.13 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Figure 16.14 Leading Industry Players: Distribution by Number of Clinical Trials
  • Figure 16.15 Leading Non-Industry Players: Distribution by Number of Clinical Trials
  • Figure 16.16 Clinical Trial Analysis: Distribution of Clinical Trials by Geography
  • Figure 16.17 Clinical Trial Analysis: Distribution of Clinical Trials by Geography and Trial Status
  • Figure 16.18 Clinical Trial Analysis: Distribution of Patients Enrolled by Geography and Trial Status
  • Figure 18.1 Global Demand for ADC Therapeutics, till 2035 (in kg)
  • Figure 18.2 Global Demand for ADC Therapeutics: Distribution by Stage of Development, till 2035 (in kg)
  • Figure 18.3 Global Commercial Demand for ADC Therapeutics, till 2035 (in kg)
  • Figure 18.4 Global Commercial Demand for ADC Therapeutics: Distribution by Target Indication, till 2035 (in kg)
  • Figure 18.5 Global Commercial Demand for ADC Therapeutics: Distribution by Antibody Origin, till 2035 (in kg)
  • Figure 18.6 Global Commercial Demand for ADC Therapeutics: Distribution by Antibody Isotype, till 2035 (in kg)
  • Figure 18.7 Global Commercial Demand for ADC Therapeutics: Distribution by Type of Payload, till 2035 (in kg)
  • Figure 18.8 Global Commercial Demand for ADC Therapeutics: Distribution by Type of Linker, till 2035 (in kg)
  • Figure 18.9 Global Commercial Demand for ADC Therapeutics: Distribution by Key Geographical Regions, till 2035 (in kg)
  • Figure 18.10 Global Clinical Demand for ADC Therapeutics, till 2035 (in kg)
  • Figure 18.11 Global Clinical Demand for ADC Therapeutics: Distribution by Phase of Development, till 2035 (in kg)
  • Figure 18.12 Global Clinical Demand for ADC Therapeutics: Distribution by Target Indication, till 2035 (in kg)
  • Figure 18.13 Global Clinical Demand for ADC Therapeutics: Distribution by Antibody Origin, till 2035 (in kg)
  • Figure 18.14 Global Clinical Demand for ADC Therapeutics: Distribution by Antibody Isotype, till 2035 (in kg)
  • Figure 18.15 Global Clinical Demand for ADC Therapeutics: Distribution by Type of Payload, till 2035 (in kg)
  • Figure 18.16 Global Clinical Demand for ADC Therapeutics: Distribution by Type of Linker, till 2035 (in kg)
  • Figure 18.17 Global Clinical Demand for ADC Therapeutics: Distribution by Key Geographical Regions, till 2035 (in kg)
  • Figure 19.1 Regional Capability Analysis: ADC Contract Manufacturing Capabilities in North America
  • Figure 19.2 Regional Capability Analysis: ADC Contract Manufacturing Capabilities in Europe
  • Figure 19.3 Regional Capability Analysis: ADC Contract Manufacturing Capabilities in Asia-Pacific and Rest of the World
  • Figure 20.1 AC Matrix: Pictorial Representation
  • Figure 20.2 AC Matrix: Overall ADC Contract Manufacturing Market Scenario (Till 2035)
  • Figure 20.3 AC Matrix: ADC Contract Manufacturing Scenario for Type of ADC Manufacturing Service Offered
  • Figure 20.4 AC Matrix: ADC Contract Manufacturing Scenario for Key Geographical Regions
  • Figure 22.1 Global ADC Contract Manufacturing Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035): Base Scenario (USD Billion)
  • Figure 22.2 Global ADC Contract Manufacturing Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035): Conservative Scenario (USD Billion)
  • Figure 22.3 Global ADC Contract Manufacturing Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035): Optimistic Scenario (USD Billion)
  • Figure 23.1 ADC Contract Manufacturing Market: Distribution by Scale of Operation
  • Figure 23.2 ADC Contract Manufacturing Market for Clinical Scale: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 23.3 ADC Contract Manufacturing Market for Commercial Scale: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 24.1 ADC Contract Manufacturing Market: Distribution by Process Component
  • Figure 24.2 ADC Contract Manufacturing Market for Antibodies: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 24.3 ADC Contract Manufacturing Market for HPAPI / Cytotoxic Payloads: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 24.4 ADC Contract Manufacturing Market for Conjugation / Linkers: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 24.5 ADC Contract Manufacturing Market for Fill / Finish: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 25.1 ADC Contract Manufacturing Market: Distribution by Type of Payload
  • Figure 25.2 ADC Contract Manufacturing Market for Tubulin Inhibitors: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 25.3 ADC Contract Manufacturing Market for Topoisomerase Inhibitors: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 25.4 ADC Contract Manufacturing Market for DNA Damaging Agents: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 25.5 ADC Contract Manufacturing Market for Others: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 26.1 ADC Contract Manufacturing Market: Distribution by Antibody Origin
  • Figure 26.2 ADC Contract Manufacturing Market for Humanized: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 26.3 ADC Contract Manufacturing Market for Chimeric: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 26.4 ADC Contract Manufacturing Market for Human: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 26.5 ADC Contract Manufacturing Market for Others: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 27.1 ADC Contract Manufacturing Market: Distribution by Antibody Isotype
  • Figure 27.2 ADC Contract Manufacturing Market for IgG1: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 27.3 ADC Contract Manufacturing Market for IgG4: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 27.4 ADC Contract Manufacturing Market for Others: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 28.1 ADC Contract Manufacturing Market: Distribution by Target Indication
  • Figure 28.2 ADC Contract Manufacturing Market for Solid Tumors: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 28.3 ADC Contract Manufacturing Market for Hematological Malignancies: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 29.1 ADC Contract Manufacturing Market: Distribution by Type of Linker
  • Figure 29.2 ADC Contract Manufacturing Market for Valine-citrulline: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 29.3 ADC Contract Manufacturing Market for SMCC: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 29.4 ADC Contract Manufacturing Market for Hydrazone: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 29.5 ADC Contract Manufacturing Market for Maleimide: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 29.6 ADC Contract Manufacturing Market for Maleimidocaproyl: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 29.7 ADC Contract Manufacturing Market for Tetrapeptide-based Linkers: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 29.8 ADC Contract Manufacturing Market for Peptide Linkers: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 29.9 ADC Contract Manufacturing Market for Others: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 30.1 ADC Contract Manufacturing Market: Distribution by Key Geographical Regions
  • Figure 30.2 ADC Contract Manufacturing Market in North America: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 30.3 ADC Contract Manufacturing Market in the US: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 30.4 ADC Contract Manufacturing Market in Canada: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 30.5 ADC Contract Manufacturing Market in Rest of North America: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 30.6 ADC Contract Manufacturing Market in Europe: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 30.7 ADC Contract Manufacturing Market in the UK: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 30.8 ADC Contract Manufacturing Market in Spain: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 30.9 ADC Contract Manufacturing Market in Italy: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 30.10 ADC Contract Manufacturing Market in Germany: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 30.11 ADC Contract Manufacturing Market in France: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 30.12 ADC Contract Manufacturing Market in Rest of Europe: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 30.13 ADC Contract Manufacturing Market in Asia-Pacific and Rest of the World: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 30.14 ADC Contract Manufacturing Market in China: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 30.15 ADC Contract Manufacturing Market in Japan: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 30.16 ADC Contract Manufacturing Market in India: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 30.17 ADC Contract Manufacturing Market in South Korea: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 30.18 ADC Contract Manufacturing Market in Australia: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 30.19 ADC Contract Manufacturing Market in Argentina: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 30.20 ADC Contract Manufacturing Market in Brazil: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 30.21 ADC Contract Manufacturing Market in Chile: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 30.22 ADC Contract Manufacturing Market in Colombia: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 30.23 ADC Contract Manufacturing Market in Israel: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 30.24 ADC Contract Manufacturing Market in Kenya: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 30.25 ADC Contract Manufacturing Market in Peru: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 30.26 ADC Contract Manufacturing Market in South Africa: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 30.27 ADC Contract Manufacturing Market in Turkey: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 30.28 ADC Contract Manufacturing Market in Saudi Arabia: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 30.29 ADC Contract Manufacturing Market in Other Countries: Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Billion)
  • Figure 31.1 Commercial ADC Contract Manufacturing Market, Forecasted Estimates, till 2035 (USD Million)
  • Figure 31.2 Commercial ADC Contract Manufacturing Market: Distribution by Process Component, Forecasted Estimates, till 2035 (USD Million)
  • Figure 31.3 Commercial ADC Contract Manufacturing Market: Distribution by Type of Payload, Forecasted Estimates, till 2035 (USD Million)
  • Figure 31.4 Commercial ADC Contract Manufacturing Market: Distribution by Antibody Origin, Forecasted Estimates, till 2035 (USD Million)
  • Figure 31.5 Commercial ADC Contract Manufacturing Market: Distribution by Antibody Isotype, Forecasted Estimates, till 2035 (USD Million)
  • Figure 31.6 Commercial ADC Contract Manufacturing Market: Distribution by Target Indication, Forecasted Estimates, till 2035 (USD Million)
  • Figure 31.7 Commercial ADC Contract Manufacturing Market: Distribution by Type of Linker, Forecasted Estimates, till 2035 (USD Million)
  • Figure 31.8 Commercial ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, Forecasted Estimates, till 2035 (USD Million)
  • Figure 32.1 Clinical ADC Contract Manufacturing Market, Forecasted Estimates, till 2035 (USD Million)
  • Figure 32.2 Clinical ADC Contract Manufacturing Market: Distribution by Phase of Development, Forecasted Estimates, till 2035 (USD Million)
  • Figure 32.3 Clinical ADC Contract Manufacturing Market: Distribution by Process Component, Forecasted Estimates, till 2035 (USD Million)
  • Figure 32.4 Clinical ADC Contract Manufacturing Market: Distribution by Type of Payload, Forecasted Estimates, till 2035 (USD Million)
  • Figure 32.5 Clinical ADC Contract Manufacturing Market: Distribution by Antibody Origin, Forecasted Estimates, till 2035 (USD Million)
  • Figure 32.6 Clinical ADC Contract Manufacturing Market: Distribution by Antibody Isotype, Forecasted Estimates, till 2035 (USD Million)
  • Figure 32.7 Clinical ADC Contract Manufacturing Market: Distribution by Target Indication, Forecasted Estimates, till 2035 (USD Million)
  • Figure 32.8 Clinical ADC Contract Manufacturing Market: Distribution by Type of Linker, Forecasted Estimates, till 2035 (USD Million)
  • Figure 32.9 Clinical ADC Contract Manufacturing Market: Distribution by Key Geographical Regions, Forecasted Estimates, till 2035 (USD Million)
  • Figure 33.1 Concluding Remarks: Market Landscape
  • Figure 33.2 Concluding Remarks: Recent Expansions
  • Figure 33.3 Concluding Remarks: Partnerships and Collaborations
  • Figure 33.4 Concluding Remarks: Clinical Trial Analysis
  • Figure 33.5 Concluding Remarks: Likely Partner Analysis
  • Figure 33.6 Concluding Remarks: Capacity Analysis
  • Figure 33.7 Concluding Remarks: Demand Analysis
  • Figure 33.8 Concluding Remarks: Market Sizing and Opportunity Analysis (1/3)
  • Figure 33.9 Concluding Remarks: Market Sizing and Opportunity Analysis (2/3)
  • Figure 33.10 Concluding Remarks: Market Sizing and Opportunity Analysis (3/3)